ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Oncorus, a start-up in Cambridge, Massachusetts, that is developing oncolytic virus therapies, has raised $79.5 million in series B financing. The firm’s lead drug candidate is an engineered herpes simplex virus that will be injected directly into tumors with the goal of killing them. The virus is also programmed to produce five proteins—including IL-12 and checkpoint inhibitors of CTLA-4 and PD-1—intended to activate the immune system to kill tumors throughout the body. Oncorus will use the money to begin clinical trials in early 2020.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter